Mutationally activated KRAS, BRAF or NRAS, which drive the oncogenic RAS/RAF/MEK/ERK pathway, are present in 55% of CRC tumors and portend poor survival [3,4,5,6]. This evidence concerns the gene MAP2K7 and colorectal carcinoma.